The manufacturers of rizatriptan and
sumatriptan contraindicate the concurrent use of
MAOIs. The US manufacturer contraindicates the use of
zolmitriptan both during, and for 2 weeks after, the use of moclobemide, whereas the UK manufacturer restricts the dose of
zolmitriptan to 5 mg in 24 hours. In the absence of any direct information it would seem prudent to apply these warnings to the use of non-selective
MAOIs.
Avoid use during and for 2 weeks after stopping an MAOI or restrict the dose of
zolmitriptan.